Archive | Melanoma News

Melanoma Research Alliance Announces $8.2 Million for 33 Grant Awards to Advance Melanoma Research

Source: Yahoo Finance, May 2019 WASHINGTON, D.C.–(BUSINESS WIRE)– In advance of Melanoma Awareness Month, the Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today announced funding for 33 innovative research awards totaling $8.26 million. The newly selected research awards will address critical unmet needs in melanoma detection, prognostication and treatment. Five awards […]

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Predictive Utility of ctDNA in Melanoma Spurs Calls for Its Inclusion in Clinical Trials

Source: Cancer Therapy Advisor, May 2019 The detection of circulating tumor DNA (ctDNA) before surgery independently predicted survival outcomes among patients with high-risk stage III melanoma in a study recently published in the Annals of Oncology.1 Although further validation is required, the study findings, along with the growing body of evidence that shows the prognostic utility of […]

Read the full story

Posted in Melanoma News

Addressing Challenges With BRAF Inhibitors in Melanoma

Source: OncLive, May 2019 Transcript: Hussein A. Tawbi, MD: BRAF inhibitors, specific BRAF inhibitors—in that case specific to the BRAF V600E mutations—transformed the care of patients with melanoma because we managed to induce really high response rates really quickly in those patients. But we also learned, as soon as we started doing that, that it does come at […]

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Time to recurrence of metastatic melanoma not associated with survival rates

Source: Healio, May 2019 In patients with metastatic melanoma, the timing of advanced disease was not associated with the timing of first distant recurrence, according to a multicentric cohort study. Study subjects were enrolled in the French MelBase database from March 1, 2013, to Sept. 1, 2017, and were treated with first-line immunotherapies, targeted therapies or […]

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest